Uutisia, analyysejä ja markkinakalenteri


ABLYNX N.V.15 min viivästetty

Muutos0% Viimeisin23,15 USD
Osto Myynti Lue lisää


08:00 REGULATED INFORMATION GHENT, Belgium, 14 September 2017 - Ablynx[Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 249,563 common shares have been issued by the Company in exchange for 878,950 as the result of the exercise of warrants. As a result of this transaction, Ablynx now has 61,419,295 shares outstanding. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,622,414 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds. About Ablynx Ablynxis a biopharmaceutical company engaged in the development ofNanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than45 proprietary and partnered programmesin development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck&Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found onwww.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Lies Vanneste Director Investor Relations t: +32 (0)9 262 01 37 m: +32 (0)498 05 35 79 e: lies.vanneste@ablynx.com Follow us onTwitter @AblynxABLX Ablynx media relations: Consilium Strategic Communications Mary-Jane Elliott, Philippa Gardner, Sukaina Virji t: +44 (0)20 3709 5700 e: ablynx@consilium-comms.com pdf version of the press release http://hugin.info/137912/R/2133917/816373.pdf --------------------------------------- This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Globenewswire © GlobeNewswire
Nordnetissä voit säästää ja sijoittaa osakkeisiin, rahastoihin, ETF:iin ja muihin tuotteisiin. Ilman kiinteitä kustannuksia ja edulliseen hintaan.

Rahoitusvälineiden arvo voi nousta tai laskea. On olemassa riski, ettet saa sijoittamiasi varoja takaisin. Historiallinen kehitys ei ole tae tulevasta tuotosta. Sinun tulee perehtyä rahastoesitteeseen ja avaintietoesitteeseen ennen kuin sijoitat rahastoihin. Rahastoesitteen saat rahastoyhtiöltä ja avaintietoesitteen löydät nordnet.fi-sivustolta rahaston yleiskatsaus -sivulta sekä toimeksiantosivulta.